Aneuploidy and Ig light chain restriction were used as separate, independent tumor specific markers t o study 26 patients with multiple myeloma t o determine whether bone marrow B cells, as defined by CD19 expression, are clonally related t o myeloma plasma cells. Specimens were characterized using multidimensional flow cytometry t o identify the presence of clonality in both the B lymphoid and plasma cell populations using both surface and cytoplasmic staining with antibodies specific for kappa or lambda Ig light chain. In none of the patients with multiple myeloma were CD19' cells found t o be clonally restricted t o kappa or lambda. The monoclonal plasma cells (MPC) were found t o be uniformly negative for CD10, CD19, and CD34, while the CD19+ B lymphoid cells present within the samples expressed normal intensities and relationships of these antigens, which al-HE IDENTITY OF the cell of origin of myeloma has T remained elusive and controversial. Hematopoietic marrow cells at differing stages of development including stem cells, pre-B lymphocytes, and mature B lymphocytes have all been implicated.'.' A number of investigators have reported finding evidence of peripheral blood B lymphocyte involvement in the myeloma clone using either flow cytometry or molecular techniques.'-' It has been postulated that clonal B lymphocytes, characterized by the surface expression of CD 19, contribute to the growth of the myeloma cell population. These cells have been presumed to be malignant progenitors that are responsible for, or contribute to, expansion and self-renewal of the myeloma clone.
Aneuploidy and Ig light chain restriction were used as separate, independent tumor specific markers t o study 26 patients with multiple myeloma t o determine whether bone marrow B cells, as defined by CD19 expression, are clonally related t o myeloma plasma cells. Specimens were characterized using multidimensional flow cytometry t o identify the presence of clonality in both the B lymphoid and plasma cell populations using both surface and cytoplasmic staining with antibodies specific for kappa or lambda Ig light chain. In none of the patients with multiple myeloma were CD19' cells found t o be clonally restricted t o kappa or lambda. The monoclonal plasma cells (MPC) were found t o be uniformly negative for CD10, CD19, and CD34, while the CD19+ B lymphoid cells present within the samples expressed normal intensities and relationships of these antigens, which al-HE IDENTITY OF the cell of origin of myeloma has T remained elusive and controversial. Hematopoietic marrow cells at differing stages of development including stem cells, pre-B lymphocytes, and mature B lymphocytes have all been implicated.'.' A number of investigators have reported finding evidence of peripheral blood B lymphocyte involvement in the myeloma clone using either flow cytometry or molecular techniques.'-' It has been postulated that clonal B lymphocytes, characterized by the surface expression of CD 19, contribute to the growth of the myeloma cell population. These cells have been presumed to be malignant progenitors that are responsible for, or contribute to, expansion and self-renewal of the myeloma clone.
CD19 is a pan B-lymphocyte antigen that appears early in B-cell ontogeny and disappears with differentiation to plasma cells.'" If CD19+ B lymphocytes are part of the myeloma clone, there should be evidence of myeloma specific genetic and phenotypic markers in this population. Therefore, if myeloma plasma cells lack CD19 expression, then CDI 9' cells represent a phenotypically distinct population of B lineage cells that can be characterized for the presence of the genetic changes associated with myeloma. DNA aneuploidy has been used as a genetic marker of malignancy and can be detected by flow cytometry in up to 80% of myeloma patients." When detection of aneuploidy is combined with lowed them t o serve as internal positive controls. Combined analysis of cell surface antigen expression and DNA content allowed plasma cell populations t o be characterized for aneuploidy without interference from normal bone marrow cells. The MPC, detected on the basis of bright CD38 expression (CD38"). demonstrated DNA aneuploidy in 65% of cases (DNA index range of 0.9 t o 1.3). These aneuploid DNA distributions had typical cell cycle profiles (including GI, S, and G2 + M) expected of a proliferating population. In all cases, DNA aneuploidy was confined almost entirely t o the CD38+', CD19-malignant plasma cells, while cells expressing CD19 were diploid. These results support the concept that myeloma is a disease process mediated by self-replicating, late compartments of B-cell ontogeny.
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other phenotypic analyses, it is possible to ascertain the presence or absence of aneuploidy in distinct cell populations.
This study was designed to establish the relationship between myeloma plasma cells and the CD19' B lineage cells present in the bone marrow. Multidimensional flow cytometry" (MDF) was used to identify and to phenotype monoclonal plasma cell populations (MPC). Plasma cells, mature B cells, and B lymphoblasts (LB) were examined for light chain restriction, as determined by analysis of both cell surface and intracytoplasmic Ig light chain expression. Additional surface antigens were also assessed to aid in delineation of MPC to allow precise phenotyping and clear distinction from other cells that have previously been suggested to be myeloma precursors by single parameter flow cytometric methods. Finally, cell surface antigen expression was combined with propidium iodide (PI) staining to identify aneuploidy as an independent neoplastic marker and to evaluate cell cycle status of phenotypically defined cell populations. ''-
MATERIALS AND METHODS
Patient samples. Patient's marrow samples were obtained during diagnostic workup for suspected myeloma at Cytometry Associates, or after referral for bone marrow transplantation with an established diagnosis of multiple myeloma at the Fred Hutchinson Cancer Research Center (FHCRC). In several cases, peripheral blood studies were also performed. Consent was obtained in accordance with the policies of the Internal Review Board at the FHCRC. Patients with MPC were identified by demonstrating clonal light chain restriction by exclusive cytoplasmic staining of plasma cells for either kappa or lambda, and the percentage of malignant cells in the samples was determined on that basis.
A mononuclear cell preparation was obtained from heparinized peripheral blood and marrow aspirates using ficoll-hypaque (density = I ,077) separation. Cells were washed twice in phosphate-buffered saline (PBS) with 2% fetal calf serum (FCS) and 0.1% sodium azide to remove the presence of light chain Ig containing plasma, and adjusted to a concentration of 2 x 106/mL. Mononuclear cell isolates for cell surface staining were added to monoclonal antibody cocktails conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), and Peridinin-chlorophyll-a (PerCP) consisting of CD45-PerCP (Beckton-Dickinson, San Jose, CA), an irrelevant control mouse IgG monoclonal antibody (MsIgG-FITC), CD19-PE (Dako, Carpinterid. CA), and anti-kappa-FITC or anti-lambda-FITC (both Dako) and Su$ace and cytoplasmic light chain Ig staining.
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For personal use only. on November 16, 2017. by guest www.bloodjournal.org From incubated for 20 minutes at room temperature (RT). For detection of cytoplasmic antigens, surface light chains were blocked using saturating concentrations of pure unconjugated antibodies directed at the antigen incubated at RT for 30 minutes. Following the blocking procedure, excess antibody was removed with a single wash in PBS containing 2% FCS and 0.1% NaN3. The cells were stained with CD38-PE at RT for 20 minutes and permeabilized with PermeaFix (Ortho Diagnostics, Raritan, NJ) using a 40-minute RT incubation. The cells were then washed twice in PBS followed by incubation for 20 minutes at RT with FITC-conjugated polyclonal antibodies directed at kappa or lambda light chains. Light chain restriction analyses were performed using a FACSCAN (Becton-Dickinson, San Jose, CA) or a Cytoron Absolute (Ortho, Raritan, NJ). Listmode files of 30,000 events were analyzed using WinlistTM software (Verity Software House, Topsham, ME). Several different projections of parameters were taken and analyzed simultaneously so that multidimensional, color-related displays were used to observe relationships between multiple signal^.'^,^' Multidimensional flow cytometry, as used in this study, correlates multiparameter data for simultaneous analysis, creating a multidimensional space for identifiaction of each cell cluster."
Ficoll-hypaque separated mononuclear cells were stained with saturating concentrations of anti-CD19-FITC (Gentrak, Plymouth Meeting, PA), anti-CD38-FITC (Gentrak) and MsIgG-FITC (irrelevant isotype-specific irrelevant antibody) and incubated at RT for 30 minutes. Cells were washed twice in PBS followed by dropwise addition of 1 mL of 70% ethanol to the cell pellet. The cells were lightly vortexed during the addition of ethanol and then were fixed ovemight at 4°C. Excess ethanol was removed by one wash, 500 p L RNAse added and cells were incubated at RT for 30 minutes. DNA was then stained by incubating in 500 pL PI (20 pglmL) for at least 2 hours at 4°C.
The PI-stained cells were analyzed using an EPICS 752 (Coulter Electronics, Hialeah, FL) with 100 mW at 488 nm. The ploidy and S-phase of electronically isolated CD19' and CD38' cells were determined using a DNA modeling system (Modfit, Verity Software House). The determination of aneuploidy was based on the collection of three individual histograms (total cells, CD38". and CD19+). Each histogram was gated on peak versus area signals to ensure single nuclei events by eliminating doublets." A total of 50,000 events were collected for each histogram using a discriminator level above 5%.
Mononuclear cell isolates of peripbera1 blood and marrow were stained with CD45-PerCP and combinations of the following directly conjugated antibodies with associated fluorochromes as follows: (1) CD19-FITC, CD38-PE; (2) CD10-(AMAC, Westbrook, ME), CD38-PE; (5) CD38-FITC, CD34-PE (BD), and (6) CD38-FITC, CD56-PE (Gentrak). Dual FITC and PE control antibodies used were isotype-specific direct conjugates of irrelevant antibodies. FITC, CD38-PE; (3) CD20-FITC, CD38-PE; (4) CD28-FWC
RESULTS

Patient characteristics.
Demographics on 26 patients with bone marrow aspirates having either DNA aneuploid or diploid MPC are included in Table 1 . Of these patients, 12 had received prior therapy, while 14 were presenting de novo. Patient ages ranged from 30 to 82 years old. Peripheral blood studies were performed in five patients and included assessment of peripheral blood DNA aneuploidy in two patients.
Discrimination of monoclonal plasma cells from other leukocytes. Multidimensional analyses can distinguish MPC from normal B-lymphoid cells and other leukocytes by combining multiple cell surface antigens with two light scatter parameters." Since the complete separation of these two cell populations using five dimensional analysis is difficult to depict in two dimensional displays, analysis of a single patient's data serves to illustrate the procedure (Figs 1, 2, and 3).
Initial screening of the samples involved collecting the forward (FSC) versus orthogonal side scatter (SSC) pattern to eliminate excessive debris (Fig IA) . The SSC versus CD4S pattern was then generated to determine the distinct cell populations present within the specimen (Figure lB) ." Plasma cells were identified separately on the basis of bright CD38 staining versus SSC (Fig IC) ." The plasma cells expressed the highest levels of CD38 (Red, Fig 1C) while the lymphoblasts (early B lineage cells) expressed IO-fold less CD38 (Green, Fig 1C) . The CD38++ cells exhibited high levels of either cytoplasmic kappa or lambda light chain (Fig 1D-F) with associated clonal light chain restriction, confirming that they were myeloma plasma cells. In contrast, the lymphoblasts and lymphocytes identified by CD19 and CD45, or CD19 versus CD38, expressed lower amounts of cytoplasmic kappa or lambda, as compared with the MPC (Fig 2A-C) , and did not show clonal restriction. An exception to these findings was patient no. 11 with plasma cell leukemia in whom MPC in the peripheral blood exhibited only a fivefold, rather than 10-fold, increase in CD38 expression as compared with the other CD38 positive cells. The proportion of MPC per nucleated cell ranged from 0.3% to 100% in bone marrow (Table 1 ) and 0.2% to 70% in peripheral blood ( Table 2 ). The use of MDF has previously been shown to have a sensitivity allowing detection of MPC down to a level of O.2%.I9
Coexpression of other lineage specific and lineage associated surface markers on the myeloma cells was also determined. Once the CD38" population was defined as clonal by light chain restriction, it was then possible to use the high intensity of CD38 expression to identify the malignant plasma cells for subsequent phenotyping. The CD38++ MPC from all patients studied were negative for surface expression of CD19 and CDlO (Table 3) . These markers clearly distinguish the MPC from the residual B lymphoid cells that express CD19. In nine of 26 bone marrows, MPC showed weak surface expression of CD20 (Table 3) . Myeloma cells from 15 of 17 patients tested were positive for surface CD56 expression, and eight of 13 patients tested were positive for surface CD28 expression. All patients evaluated in this study showed MPC expression of one or the other of these two antigens. CD4S expression was found to be heterogeneous on MPC, both within a given patient and between different patients, with a majority of cells usually showing absent or reduced expression relative to lymphoid cells (Fig IB) . Therefore, CD45 expression was not used as a marker to specifically identify myeloma cells.
Antigen expression of marrow B lymphoid cells in myeloma. Immunophenotypic analysis of the remainder of the B-cell compartment using MDF showed that these cells had phenotypes of normal B lymphoid cells and did not show clonal light chain restriction (Figs 2 and 3) . The B lymphoblasts exhibited low levels of CD45 expression and had decreased SSC as compared to mature B and T lymphocytes as previously reported (green v blue, Fig lB) ." There- fore, the early B lymphoid cells and mature lymphocytes were clearly delineated using CD45, CD38, and side scatter (Fig 1B and C) . Enumeration and characterization of B lymphoid and other cells was accomplished by either directly gating on the discrete cell population or by backgating using three-color combinations to isolate cell populations of interest." Both immature B lymphoblasts and mature B lymphoid cells expressed CD19. The B lymphoblasts demonstrated CDlO with increasing expression of CD20 on the maturing B cells (green, Fig 3B and C, respectively) . These immature lymphoid cells expressed small amounts of cytoplasmic Ig (green, Fig 2B and C, respectively) and included a small population of cells with nonclonal surface Ig expression. Mature B lymphoid cells expressed CD20 without CDlO and also showed nonclonal cell surface Ig expression (blue, Fig 3B through E) . Monoclonal plasma cells (red, Fig 3A  through C) showed considerably more autofluorescence than lymphoblasts and lymphocytes illustrating that different baseline autofluorescence generates different negative thresholds for different cell populations.
Neither clonal surfacekytoplasmic light chain restriction, nor significant skewing towards the MPC specific light chain, were detected in B lymphoid cell populations from specimens of bone marrow (Table 4 ) and peripheral blood (Table  2) . In some instances, mature B lymphocytes were found to have increased expression of the opposite light chain to that found on the MPC. In these cases, the kappa:lambda ratios were within normal limits, and these results probably reflect statistical variation. In addition, the proportion of CD19' B cells in the majority of bone marrow aspirates (2.1% -+ 2.4% of total cells) was reduced as compared with a previously established normal reference value (6.3% -+ 4.3%).'" Eight patients were tested for CD34 expression and in no case was it detected on MPC (Table 3 and Fig 4) . Using backgating analysis on the CD45 and the SSC histogram (as for Fig lC) , it was possible to make a clear distinction between brightly positive CD38 myeloma cells and normal marrow progenitors'O,'O that expressed both CD38 and CD34. Only the CD38+', CD34-cells were clonally restricted with intracytoplasmic expression of either kappa or lambda light chains. The CD34+ progenitor cells in the bone marrow specimens had phenotypes consistent with normal hematopoietic development."
DNA and S-phase analysis in specimens with aneuploidy. DNA aneuploidy was used as an additional tumor specific marker to examine MPC and CD19' B lymphoid cells. The separate populations of cells were identified by cell surface antigen staining with HTC-conjugated antibodies in combination with PI staining to detect DNA aneuploidy. PI staining has a low coefficient of variation of the G1 peak (below 3%), thereby allowing resolution of small changes in DNA content often found in myeloma including changes in the DNA index (DI) of 0.1 or greater." 
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used to exclude doublets. DNA aneuploidy was found in 65% of patient bone marrow samples (17 of 26, Table 1 ). In peripheral blood specimens, DNA aneuploidy was detected in two of five different patient samples ( Table 2 ). The range of the DI was 0.90 to 1.40 with a mean of 1.1 in bone marrow (diploid = 1.0).
Three separate histograms (50,000 events) were collected for each DNA aneuploid specimen; these included all cells, those gated on CD38++ cells, and those gated on CD19+ cells. As shown in Fig 5, the DNA aneuploid population was completely confined to the CD38++ population, while the CD19+ cells were diploid. In all 17 aneuploid specimens, the CD19+ fraction was always diploid, whereas the CD38++ cells were aneuploid. In separate studies using mixing experiments, the use of dual DNA and surface antigen staining allowed detection of DNA aneuploidy in as few as 0.5% of aneuploid cells added to a diploid population (data not shown). Therefore, in each case, there were <0.5% aneuploid cells in the CD19' population of cells.
Monoclonal plasma cells are cycling. The CD38" DNA aneuploid and diploid MPC were found to have a normal cell cycle profile with G1, S, and G2iM components indicating the presence of a proliferating CD38++, CD 19-compartment in this disease. This was particularly pronounced in the DNA aneuploid cells, but was also identified in the specimens with diploid MPC. The S-phase fraction of the aneuploid and diploid MPC in bone marrow ranged from 0% to 12.0% and in the peripheral blood specimens ranged from 0.2% to 1.8%. Seventeen of 26 bone marrow aspirate specimens and six of six peripheral blood specimens had an S-phase present in the MPC population that was greater than zero, indicating proliferation of the clone.
DISCUSSION
One hypothesis as to the origins of plasma cell populations found in myeloma is that they develop from cells at earlier stages of B-cell ontogeny, 1.3m including from within the hematopoietic stem cell compartment.*' An alternative hypothesis is that the tumor is restricted to self-replicating plasma cells without replenishment from earlier B lymphocyte precursors. If tumor proliferation is occurring in early stages of B-cell ontogeny, evidence of disturbed B-cell maturation should be present. In addition, there should be tumor markers detectable in cells at different stages of B-cell differentiation. However, these markers would not be identified in the earlier B lymphoid cells if tumor replication was restricted to the plasma cell compartment.
This study of myeloma patients used MDF and DNA aneuploidy analysis to explore whether B lymphoid cells, as defined by CD19 expression, share genetic markers with the malignant clone. The combined use of surface staining with CD38 and DNA staining with PI has previously been shown to be an accurate method for identifying monoclonal aneuploid plasma cells in myeloma and evaluating their SAlthough DNA staining with bromodeoxyuridine (BRDU) and tritiated thymidine has also previously been used to evaluate myeloma proliferation, the PI method has some advantages in that the malignant cells need not comprise a majority of cells since they can be isolated electronically based on surface phenotype for separate DNA analysis. A dual-staining technique was necessary to specifically study minority populations of MPC (in some cases <5%) for DNA content and S-phase that may not be detectable without surface staining of the mye10ma.l~ Similarly, DNA content of the small CD19+ cell populations could only be measured because these populations could be specifically identified by surface marker expression.
Monoclonal aneuploid or diploid plasma cells could be identified based on high CD38 expression and monoclonal light chain expression in the cytoplasm, and these cells were uniformly negative for CD19 expression. Normal nonclonal pre B and mature B lymphoid cells served as an internal positive control for the comparison of CD19 and CD38 expression. It has previously been shown that a high percentage (97% 5 2%) of the aneuploid cells segregate with the CD38++ phen~type.'~ While very small populations of aneuploid cells expressing a lower amount of CD38 were detected in some patients, these cells were not detected in the CD19+ population, and other phenotypic characteristics of these cells remain to be determined. The absence both of detect- (Table 1) 
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able aneuploidy and of light chain restriction or skewing of the CD19' cells suggests that these CD19+ B lymphoid cells were not genetically identical with the MPC clone. Further, we did not find disturbed or aberrant patterns of expression of normal B-cell maturation markers in the marrow as can be detected in acute lymphoblastic leukemia and non-Hodgkin's lymphoma.22 In several cases, S-phase analysis showed that significant proliferation was occurring in a CD38++/ CD 19-cell population. This suggests that self-replication of MPC occurs and could account entirely for tumor growth without the need for myeloma progenitors from earlier in Bcell ontogeny.
With the techniques used in this study, it is possible to detect 0.5% aneuploid B lymphoid cells among normal B cells. Furthermore, since the mean percent of CD19+ B cells in the marrow was 2.3%, then the percent of aneuploid CD19+ B cells that could have been present without detection among the total cell population in the specimens was approximately 0.01% (0.5 X 0.023). This calculation is in keeping with the observation that aneuploid CD19' cells were not detected in list mode files of at least 50,000 cells. Overall, these findings are consistent with those made by some other investigators2'-2' who found no evidence of an expanded B-cell compartment in myeloma patients. The presence of rare CD19+ aneuploid cells in the patients studied cannot be absolutely excluded. However, if these cells are present, they represent a very small subpopulation of the malignant clone.
Results of molecular studies also have suggested that tumor replication is occurring late in B-cell ontogeny. Southern Flow cytometric identification of myeloma cells and their phenotypic characteristics depends on accurately identifying and electronically isolating the MPC clone.'0,'2 A multidimensional approach is necessary to delineate the relevant cell populations, as no single marker distinguishes plasma cells from all other marrow leukocytes. It was only after confirming clonal light chain restriction of the CD38'+ population that intensity of CD38 expression was used to define the plasma cells for subsequent phenotypic analysis. An important additional factor is that the background nonspecific fluorescence is dramatically differenti between plasma cells and other lymphoid cells as illustrated in Figs 2 and 3. In this example, plasma cells could erroneously be attributed the expression of CD20 and CDlO if they were not delineated as a separate population for analysis, and if different control reference backgrounds were not set for the separate populations.
Using an MDF approach to phenotyping, we did not detect expression of CD34, CD10, or CD19 on MPC. Because some heterogeneity of surface markers between tumors from different patients does exist, these markers may be expressed on the MPC in a minor subset of patients. The absence of CD34 expression on MPC is consistent with polymerase chain reaction (PCR) studies that did not detect myeloma IgH rearrangements in highly purified CD34 positive cell populations obtained from bone marrow of myeloma pat i e n t~.~~ CD34 expression was also not detected on mature peripheral blood B lymphocytes (data not shown) as previously has been r e p~r t e d .~.~ The absence of CDlO expression on MPC from 24 patients suggests that CD10+ myeloma is an uncommon phenotype, in contrast to the findings of othersS3 However, the possibility that CDlO is expressed on rare myeloma cells is not excluded by our data. Even if it were demonstrated that rare tumor cells from all myeloma patients express a marker usually expressed earlier in B-cell ontogeny, it would remain another matter to prove that these cells have a role as the so-called myeloma progenitor cells.
We have confirmed that CD56 and CD28 are frequently expressed on myeloma ~e l l s .~~~~-~~ CD56 and/or CD28 was present on MPC in all cases tested suggesting that these antigens could be targets for therapies using monoclonal antibodies. Because neither CD56 nor CD28 was expressed on MPC in every case, expression of these antigens on myeloma cells should be carefully confirmed by MDF in each individual case before using them to monitor disease.
In contrast to our observations, some investigators have reported detection of marrow myeloma B-cell precursor^'.^ and clonal myeloma B-cell populations (including up to 80%) in the peripheral b l~o d .~.~ One conceivable explanation for differences between our findings and some previous reports is that phenotypic differences exist between peripheral blood and marrow B cells. In five patients reported here, there was no discordance noted between marrow and peripheral blood MPC or B lymphoid immunophenotype. Further, as marrow samples usually contain an admixture of peripheral blood, expanded aneuploid populations of CD 19+ cells would have been detected if present. In addition, treatment effects do not explain the variance between other studies and our observations because prior therapy had no effect on our results (14 of 26 patients had received no prior therapy).
A recent approach to identifying myeloma precursor cells has involved PCR studies to detect myeloma IgH rearrangements in cell populations obtained by cell sorting. This has led to reports of myeloma IgH rearrangements being detected in CDlO postive4' and CD19' B-cell population^.^.^ Caution is required in interpreting these PCR-based studies. Because of the extreme sensitivity of PCR, sorting purities need to be absolute to exclude plasma cells from the sorted population. Plasma cells could inadvertently be sorted into the CD10+ or CD19+ cell populations as a result of the increased autofluorescence of these cells unless specific measures using electronic gating are taken to exclude the MPC. Furthermore, although IgH rearrangement sequences are highly reliable clonal markers of B cells, they are not per se markers of malignancy. None of the PCR-based studies have yet shown that another independent marker of malignancy is also found in the same B cells that have the IgH clonotypic marker. The detection of clonal myeloma IgH rearrangements in CD19' cells also could suggest that a small clone of premalignant or premyelomatous B cells persists after one cell transforms into the malignant clone (as manifested by the presence of aneuploidy in some cases), and that this population does not actively contribute to myeloma clonal expansion. Definitive evidence as to the genetic and functional relationships between myeloma plasma cells and other B lineage cells, therefore, requires testing of highly purified Bcell populations free of contaminating plasma cells. Only then can the presence or absence of tumor-specific genetic changes associated with malignant transformation be assessed with PCR or equivalent techniques.
Current treatments for myeloma remain unsatisfactory"' and even with intensified therapy in the setting of bone marrow transplantation, relapses remain a major impediment to the success of both autografting and all0grafting.4'~'~ New strategies for treating myeloma could involve specific targeting of the malignant phenotype with monoclonal antibodies. Based on our data, the specific targeting of conventional B-cell phenotype^^"^ would appear to be insufficient for either treatment of myeloma or purging of stem cell grafts because the CD19-MPC appear to be a self-replicating population. Directing attention to antigens such as CD56, CD28, and CD384s,46 may prove more effective in this regard.
In an autografting setting where autografts are usually contaminated with some level of tumor,'" CD34 selection of peripheral blood stem cells34 might be followed by active purging of tumor cells with antibodies against CD28 and/or CD56 to generate a tumor free graft. Targeted radiotherapy:8.49 perhaps using monoclonal antibodies against CD38,
